Delving into the Latest Updates on Tianjin Lisheng Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Other Diseases

Nervous System Diseases

Endocrinology and Metabolic Disease

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	13
Endocrinology and Metabolic Disease	12
Infectious Diseases	6
Immune System Diseases	5
Hemic and Lymphatic Diseases	4
Neoplasms	3

Top 5 Drug Type	Count

Small molecule drug	30

Top 5 Target	Count

H1 receptor(Histamine H1 receptor)	2
GR(Glucocorticoid receptor)	2
NCC(Thiazide-sensitive sodium-chloride cotransporter)	2
D2 receptor(Dopamine D2 receptor)	1
Kir6.2 x SUR1	1

主要目的：以持证商为TEIJIN PHARMA LIMITED的非布司他片（商品名：Feburic®（菲布力®），规格：40mg）为参比制剂，以天津力生制药股份有限公司研发的非布司他片（40mg）为受试制剂，评价两种制剂在中国健康受试者中空腹和餐后状态下的生物等效性。次要目的：观察受试制剂和参比制剂在中国健康受试者中的安全性。

[Translation]

Primary objective: Using Febuxostat tablets (trade name: Feburic®, specification: 40 mg) from TEIJIN PHARMA LIMITED as the reference preparation and Febuxostat tablets (40 mg) developed by Tianjin Lisheng Pharmaceutical Co., Ltd. as the test preparation, evaluate the bioequivalence of the two preparations in fasting and postprandial states in healthy Chinese subjects. Secondary objective: Observe the safety of the test preparation and reference preparation in healthy Chinese subjects.

Start Date08 Oct 2024

Sponsor / Collaborator

Tianjin Lisheng Pharmaceutical Co., Ltd.

CTR20243304 / Active, not recruitingNot Applicable

氨茶碱片在健康成年受试者中单中心、随机、开放、四周期重复交叉、空腹及餐后状态下单次给药生物等效性试验

[Translation] A single-center, randomized, open-label, four-period repeated crossover bioequivalence study of aminophylline tablets in healthy adult subjects under fasting and fed conditions

主要研究目的以天津力生制药股份有限公司生产的氨茶碱片[0.1g（按C2H8N2(C7H8N4O2)2·2H2O计）]为受试制剂，サンノーバ株式会社生产的氨茶碱片（100mg，商品名：Neophyllin®）为参比制剂，研究受试制剂与参比制剂的吸收速度及吸收程度，考察受试制剂和参比制剂的生物等效性。次要研究目的观察受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

Main research purpose Using aminophylline tablets [0.1g (calculated as C2H8N2(C7H8N4O2)2·2H2O)] produced by Tianjin Lisheng Pharmaceutical Co., Ltd. as the test preparation and aminophylline tablets (100mg, trade name: Neophyllin®) produced by Sannoba Co., Ltd. as the reference preparation, the absorption rate and degree of the test preparation and the reference preparation were studied, and the bioequivalence of the test preparation and the reference preparation was investigated. Secondary research purpose To observe the safety of the test preparation and the reference preparation in healthy subjects.

Start Date29 Sep 2024

Sponsor / Collaborator

Tianjin Lisheng Pharmaceutical Co., Ltd.

CTR20243017 / RecruitingNot Applicable

格列吡嗪控释片在健康受试者中随机、开放、两制剂、单剂量、双周期、双交叉空腹和餐后状态下的生物等效性试验

[Translation] A randomized, open-label, two-dose, single-dose, two-period, double-crossover bioequivalence study of glipizide controlled-release tablets in healthy subjects under fasting and fed conditions

主要目的：以Pfizer Pharmaceuticals LLC公司生产的格列吡嗪控释片（瑞易宁®，5mg/片）为参比制剂，以天津力生制药股份有限公司生产的格列吡嗪控释片（5mg/片）为受试制剂，通过随机、开放、两制剂、单剂量、双周期、双交叉试验设计，初步比较两制剂的药代动力学特征，并初步评价两制剂在空腹和餐后给药条件下的生物等效性。次要目的：初步评价中国健康受试者单次空腹及餐后口服格列吡嗪控释片受试制剂和参比制剂后的安全性。

[Translation]

Main purpose: Using glipizide controlled-release tablets (Reiyi Ning®, 5 mg/tablet) produced by Pfizer Pharmaceuticals LLC as the reference preparation and glipizide controlled-release tablets (5 mg/tablet) produced by Tianjin Lisheng Pharmaceutical Co., Ltd. as the test preparation, a randomized, open, two-preparation, single-dose, double-period, double-crossover trial design was used to preliminarily compare the pharmacokinetic characteristics of the two preparations and preliminarily evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary purpose: Preliminary evaluation of the safety of the test preparation and reference preparation of glipizide controlled-release tablets after a single fasting and postprandial oral administration in healthy Chinese subjects.

Start Date30 Aug 2024

Sponsor / Collaborator

Tianjin Lisheng Pharmaceutical Co., Ltd.

100 Clinical Results associated with Tianjin Lisheng Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Tianjin Lisheng Pharmaceutical Co., Ltd.

Login to view more data

7

Literatures (Medical) associated with Tianjin Lisheng Pharmaceutical Co., Ltd.

02 Feb 2024·The Journal of Organic Chemistry

Visible Light-Driven Flexible Synthesis of α-Alkylated Glycine Derivatives Catalyzed by Reusable Covalent Organic Frameworks

Article

Author: Tian, Hua ; Zhao, Zhen ; Fu, Hua ; E, Junnan ; Wang, Luohe ; Shi, Liangliang ; Yang, Xiaobo ; Bu, Xiubin ; Tian, Yao

Herein, we report a heterogeneous visible light-driven preparation of α-alkylated glycine derivatives. This approach employed a β-ketoenamine-linked covalent organic framework (2D-COF-4) as the heterogeneous photocatalyst and N-hydroxy phthalimide (NHPI) esters as the alkyl radical sources. Numerous glycine derivatives, including dipeptides, were precisely and efficiently alkylated under visible light-driven reaction conditions. Based on the excellent photoactivity and organic reaction compatibility of 2D-COF-4, this alkylation could proceed flexibly in a green solvent (ethanol) without any other additives. The photocatalyst and phthalimide were fruitfully recycled with a simple workup procedure, revealing a high ecoscale value and low environmental factor (E-factor).

Xiandai Yaowu Yu Linchuang

Cyclin-dependent protein kinases 4/6 inhibitor ribociclib

Author: Chen, Chang-qin ; Cui, Yan-li ; Jin, Yu-jie ; Xie, Xue-xing ; Lu, Yan-qin

A review, with 14 references, is given on the synthetic route, pharmacol. action, and clin. research of a cyclin-dependent protein kinases 4/6 inhibitor, ribociclib.The incidence of breast cancer is increasing year by year, and has become a major public health problem in the world.Cycle dependent protein kinase(CDK) 4/6 inhibitor can block cell cycle in G₁ phase, which can inhibit tumor growth.Ribociclib is a highly specific protein kinases 4/6 inhibitor, which can inhibit D1/CDK4 and D3/CDK6 cell cycle, and has potential antitumor activity.The results of clin. trials indicate that ribociclib has clin. efficacy in treatment of breast cancer, melanoma, non-small cell lung cancer, teratoma, liposarcoma, and glioblastoma.

Xiangliao Xiangjing Huazhuangpin

Biological activities of Scutellaria Baicalenisis Georgi and their applications in cosmetics

Author: Li, Hong

A review.The resources, chem. constituents, extraction methods, bioactivities of Scutellaria Baicalenisis Georgi which was well-known traditional Chinese medicine and their applications in cosmetics were reviewed.With wide bioactivities of anti-bacterial, anti-fungi, anti-inflammatory, anti-allergy, anti-oxiding, free-radical scavenging, anti-radiation of UV, anti-radiation and inhibition of tyrosinase activity, baicalin and baicalein which were the main constituents in S. baicalenisis Georgi were used to prepare functional cosmetics for treating acne, sun-protecting, freckle-alleviating, skin-whitening, skin-antiaging and wrinkle-alleviating, to prepare oral products for treating periodontitis and to prepare lotions for external use.In conclusion, baicalin, baicalein and other main constituents in S. baicalenisis Georgi were the natural, high-effective, multi-functional cosmetic additives with all freckle-alleviating, skin-whitening, sun-protecting, anti-allergy, anti-inflammatory and anti-aging in one.

100 Deals associated with Tianjin Lisheng Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Tianjin Lisheng Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

30

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Chlorpheniramine Maleate ( H1 receptor )	Rhinitis, Allergic, Seasonal More	Approved
Atendol ( β1-adrenergic receptor )	Hypertension More	Approved
Cimetidine ( H2 receptor )	Gastroesophageal Reflux More	Approved
Itraconazole ( fungal CYP51A1 )	Mycoses More	Approved
Diphenhydramine Hydrochloride ( H1 receptor )	Hypersensitivity More	Approved